HOME > LATEST

LATEST

BUSINESS Daito Snags China Approval for Iguratimod, Its Third Product

January 7, 2026
BUSINESS China Accepts BLA for Leqembi Subcutaneous Autoinjector: Eisai

January 7, 2026
COMMENTARY Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026

January 6, 2026
ORGANIZATION FY2026 Reform Tilted toward Price Cuts despite Spillover Scrap: FPMAJ Chair

January 6, 2026
ORGANIZATION Pfizer Japan President Igarashi Takes Helm as PhRMA Japan Chair

January 6, 2026
REGULATORY MHLW Issues Guidance on Revised PMD Act Ahead of May Enforcement

January 6, 2026
BUSINESS Kyorin Licenses Lasvic to UAE’s Lunatus for Middle East Markets

January 6, 2026
REGULATORY MHLW Sets Up Drug Discovery Support Office Ahead of New Fund Launch

January 6, 2026
BUSINESS Sanofi to Transfer Jevtana Sales to Taiho from April

January 6, 2026
REGULATORY Ex-JPMA President Ueno Takes on New AMED Advisor Role

January 6, 2026
REGULATORY Cabinet OKs FY2026 Tax Reform Package, Creates Strategic Tech R&D Credit

January 5, 2026
BUSINESS Meiji Restarts Domestic 6-APA Production after 31-Year Hiatus

January 5, 2026
REGULATORY Chuikyo OKs Medical Materials Reform Outline, Price Hikes Possible for Loss-Making Devices

January 5, 2026
ORGANIZATION Industry Leaders Call for Proper Rewards for Innovation in New Year Messages

January 5, 2026
REGULATORY MHLW FY2026 Budget Hits Record 35 Trillion Yen, Drug Discovery Support Set at 7.1 Billion Yen

January 5, 2026
BUSINESS Meiji Files NDA for Nacubactam in Japan

January 5, 2026
ORGANIZATION Generic Use Rate Rises Further to 89.5% in July-September: JGA

January 5, 2026
REGULATORY Gist of FY2026 Drug Pricing Reform Outline

December 26, 2025
REGULATORY Japan Puts CEA Expansion on Hold, Sets 6-Month “Technical Discussions”

December 26, 2025
REGULATORY Chuikyo OKs FY2026 Drug Pricing Reform Outline, Scraps “Spillovers” but Adds New Follow-Up Rules

December 26, 2025

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…